Atomoxetine (Strattera) — the non-stimulant for adult ADHD

The ADHD medication people talk about less

When you think “ADHD medication”, you think Ritaline or Concerta. Few people know there’s a non-stimulant molecule, developed specifically for ADHD, with a European marketing authorisation since 2005 in children and adolescents, and used for a long time in adults: atomoxetine.

It’s known under the brand name Strattera (Lilly). It has its limits — smaller effect than stimulants, long onset — but it has a real place in adult ADHD care, especially when stimulants are problematic.

What it is

Atomoxetine is a selective noradrenaline reuptake inhibitor (NRI). It doesn’t act directly on dopamine (except in the prefrontal cortex, where noradrenergic transporters also regulate local dopamine).

Pharmacological specificities

What the evidence says — efficacy

The big meta-analyses

• Cortese 2018 (Lancet Psychiatry) ^[8] : in adults, atomoxetine is superior to placebo, but with a more modest effect size than stimulants.
• Gosling, Cortese et al. 2025 (BMJ) ^[7] : atomoxetine classified with at least moderate-certainty evidence of efficacy in adults, medium effect size.
• Asherson et al. 2014 ^[9] : integrated meta-analysis of placebo-controlled trials in adults — efficacy superior to placebo on both domains (inattention and impulsivity/hyperactivity), with stronger efficacy on inattention.
• Cheng et al. 2016 ^[10] : atomoxetine effective regardless of rater (patient and clinician), but dropouts for adverse effects more frequent than placebo.

What to remember

• Real but moderate efficacy: on average, less potent than stimulants.
• Gradual effect: builds over 4-8 weeks, then tends to continue improving up to 6 months in some studies ^[9] .
• Heterogeneous response: some people respond excellently, others little or not at all.

4-8 wks

delay before evaluating atomoxetine response

Who is atomoxetine indicated for?

French marketing authorisation indications

According to the HAS 2011 opinion ^[3] and the European marketing authorisation: ADHD in children > 6 years, adolescents and adults (if diagnosis made earlier or continuation of a treatment initiated in childhood).

Clinical situations where it’s preferred

Contraindications

Side effects

Common (≥ 1/10 or 1/100)

• Nausea, decreased appetite — often early in treatment.
• Dry mouth.
• Somnolence or insomnia (both can happen, depending on the person).
• Dizziness, headaches.
• Constipation.
• Reduced libido, erectile issues.
• Slight increase in heart rate and blood pressure.
• Fatigue.

Less common

• Sweating, hot flushes.
• Dysuria (difficulty urinating), urinary retention — anti-α1 adrenergic effect.
• Irritability, transient anxiety.

Rare but serious

• Acute hepatitis: rare but documented. Transaminase monitoring if symptoms (jaundice, dark urine, right upper quadrant pain).
• Suicidal ideation: see dedicated section below.
• Cardiovascular: rare but possible QT prolongation.

The FDA black-box warning — an honest clarification

What the warning says

In 2005, the FDA added a black-box warning (the highest level of alert) on the Strattera label ^[4] .

Source data: in paediatric trials (12 studies, 2,200 patients), 0.4% of atomoxetine patients (5/1,357) reported suicidal thoughts vs 0% under placebo. All events occurred in children ≤ 12 and in the first month of treatment. No suicides in these trials.

What it means, concretely

In adults

The signal is less clear in adults. More recent post-marketing studies ^[11] haven’t systematically confirmed the excess risk observed in the initial trials. Caution remains in order, but atomoxetine is routinely used in Europe in adolescents and adults. Discussing this risk is part of informed consent.

The French framework — a complex situation in 2025-2026

The planned Strattera (Lilly) withdrawal

Available generic alternatives

To maintain access to the molecule ^[2] , two generics are available under derogatory access:

• Atomoxetin Stada (Stada Arzneimittel laboratory).
• Atomoxetin Zentiva (Zentiva Pharma laboratory).

These products are under Compassionate Access Authorisation (AAC) — access via the e-Saturne platform, hospital circuit, more cumbersome procedure than for a standard authorised medication.

Difficult point: no generic alternative for the oral liquid form ^[2] — if your child or adult took the syrup, urgent discussion with the specialist to switch to capsule or another treatment.

Prescribing conditions

• Initial prescribing restricted to specialists: psychiatrists, neurologists, paediatricians.
• Standard prescription (no secure prescription, not Schedule I controlled substance).
• Classic prescription duration (3-6 months depending on prescriber).

The practical protocol — what to expect

Initiation

• Gradual titration: starting at low dose, stepwise increase over 1-2 weeks.
• Adult target dose: determined by prescriber based on response and tolerance.
• Patience: don’t judge efficacy before 4-8 weeks at stable therapeutic dose.

Follow-up

• Blood pressure and heart rate before initiation and at 1-3 months.
• Clinical evaluation at 4-8 weeks, then every 3-6 months.
• Mood monitoring, especially in the first weeks.
• Transaminases if hepatic symptoms (not systematic testing).

Stopping

No documented withdrawal syndrome (unlike some antidepressants) — stopping can happen without gradual tapering. But in practice, abrupt stopping brings ADHD symptoms back.

I tried Concerta: my anxiety exploded. I switched to Strattera. For the first 3 weeks, I thought it wasn’t working. By week 6, I realised I was managing my days better than ever, without the jitters. The delay is real — you have to hold on.

The honest questions people ask

”Is it worse than stimulants?”

On average, yes — smaller effect size in meta-analyses ^[8] . But for some people, atomoxetine works better (or is the only viable option), notably with marked anxiety, active addiction, or cardiovascular contraindication. The average doesn’t speak to your individual case.

”Can I stop if it doesn’t work?”

Yes, but after a long enough trial (6-8 weeks at therapeutic dose). Many people stop too early because they expect a fast stimulant-like effect — which doesn’t come. Patience is intrinsic to this treatment.

”And if Strattera disappears in 2026, what do I do?”

Generics under AAC take over. The procedure is more cumbersome (hospital-based) but functional. Your ADHD specialist is aware. Anticipate 1-2 months before 27 February 2026 with your prescriber.

”Does it make you less creative / less alive than stimulants?”

Subjective question asked by many. Stimulants have a “boost” effect some perceive; atomoxetine has a more diffuse, “background” effect, sometimes harder to feel subjectively — which doesn’t mean it isn’t working (hence clinical scales to evaluate, not just feeling).

Signals for emergency consultation

Takeaways

Go further

• Methylphenidate (Ritaline, Concerta) — adult first-line
• Lisdexamfetamine (Elvanse / XURTA) — the amphetamine prodrug
• ADHD medication shortages in France
• Managing side effects
• The diagnostic pathway